- Home
- Applications
- tumor cell
Refine by
Tumor Cell Product Applications
37 applications found
The development of highly cytotoxic drugs is needed for the success of the treatment in tumor cells. Paradoxically, the high toxicity limits its efficacy and application in vivo, causing damage to non-target organs and severe secondary effects. ...
ByNanovex Biotechnologies based in Llanera, SPAIN
Natural killer (NK) cells have long been known to play a significant role in the body’s innate immune response. They were first described in the 1970s, but only in the last 15 years has significant progress been made in understanding the complexities and therapeutic potential these cells offer in helping fight cancer and other diseases. Today, we know that NK cells not only detect and identify malignant cancer cells, but they also induce ...
ByKiadis Pharma NV based in Amsterdam, NETHERLANDS
To date, the classification of cancers has been based solely on the phenotypic and genotypic characteristics of tumor cells. A new paradigm, scientifically well established and recommended by WHO guidelines, relies on the introduction of the immune response as a new prognostic parameter to predict and refine the clinical outcomes of cancer patients. Maximize patient survival rates with an assessment of the tumor immune response. ...
ByVeracyte based in Marseille Cedex 9, FRANCE
In healthy individuals the vast majority of cfDNA derives from hematopoietic myeloid and lymph cells undergoing apoptosis. However, in individuals with cancer, a variable fraction of the cfDNA derives from tumor cells undergoing apoptosis and/or necrosis. This tumor derived fraction of cfDNA is known as circulating tumor DNA (ctDNA). The amount of ctDNA found in an individual with cancer depends on numerous parameters such as ...
ByClaret Bioscience based in Santa Cruz, CALIFORNIA (USA)
BOC Sciences is committed to supplying cost-effective products and services. We provide Peretinoin (Cas No:81485-25-8). More information, please visit the website: http://www.bocsci.com/peretinoin-cas-81485-25-8-item-84-305467.html ...
ByBOC Sciences based in Shirley, NEW YORK (USA)
The modular fashion with which Affilin® ligands can be fused together makes creating multi-specific binders an easy task. Combined with varying linker lengths, composition, and orientation, plus the optional addition of further accessory modules, our Navigo experts build the designed molecules as previously planned on the drawing ...
ByNavigo Proteins GmbH based in Halle, GERMANY
This active molecular is a selective inhibitor of ALK(anaplastic lymphoma kinase)which is a target found in NSCLC (metastatic non-small cell lung cancer).https://www.bocsci.com/ceritinib-cas-1032900-25-6-item-462148.html ...
ByAlfa Chemistry based in NY, NEW YORK (USA)
Use our platform to design antibodies that optimize binding affinity, titer, specific productivity, Immunogenicity, or other phenotypic variables of interest. Engineer antibodies that specifically kill cancer cells or equib cells with multiple functions, granting them the ability to invade human cancer-derived ...
ByTeselaGen Biotechnology, Inc. based in Portola Valley, CALIFORNIA (USA)
BOC Sciences is committed to supplying cost-effective products and services. We provide Halofuginone (Cas No:55837-20-2). More information, please visit the website: http://www.bocsci.com/halofuginone-cas-55837-20-2-item-84-71625.html ...
ByBOC Sciences based in Shirley, NEW YORK (USA)
Data from examining the immune repertoire of cancer patients can be used to identify patterns associated with positive outcomes and monitor the progress of immunotherapies in clinical trials. Single cell immune sequencing technologies provide an even more granular view of individual T cell or B cell populations following immunotherapy, providing unprecedented detail for informing cancer ...
ByiRepertoire, Inc. based in Huntsville, ALABAMA (USA)
Peptides and peptidomimetics constitute excellent tumor-specific targeting moieties and can be coupled to therapeutic and diagnostic radioisotopes via a linker and a ...
By3B Pharmaceuticals GmbH based in Berlin, GERMANY
NorthStar Medical Radioisotopes is poised to become the first-in-class supply chain for the future of therapeutic radiopharmaceuticals. Check back for progress on our non-carrier-added (n.c.a) Ac-225 and Cu-67 development ...
ByNorthStar Medical Radioisotopes, LLC based in Beloit, WISCONSIN (USA)
We have developed proprietary methods for expressing immunotherapeutic payloads in a highly controlled and specific manner within tumors. IFN-α is a well-known therapeutic that was previously administered systemically for treatment of various cancers but it is currently rarely used because of its systemic toxicity. In the tumor microenvironment, IFN-α exerts its anti-tumor activity both directly by promoting cancer cell apoptosis and ...
ByGenenta Science based in Milano, ITALY
Downregulating the immune response is necessary for the treatment of autoimmune diseases. In this aspect, the APO2L/TRAIL ligand is a key intermediate in immune cascades and is secreted in exosomes in natural conditions. Its alteration has been associated with rheumatoid arthritis. The administration of synthetic exosomes decorated with APO2L/TRAIL has been shown to be effective in reducing the hyperplasia and overall inflammation in this ...
ByNanovex Biotechnologies based in Llanera, SPAIN
Cancer is one of the leading causes of deaths in India and a major public health concern. It is estimated that there are around 1 million new cancer cases every year and as many as 5 lakh deaths occur annually. Around 71% of all cancer deaths in India occur in people 30 to 69 years of age, when adults are very productive. The burden of cancer is expected to further increase due to increase in life expectancy, heavy use of tobacco and other risk factors such as radiation, viruses, ...
ByinDNA Research Labs based in , INDIA
MarginProbe is an FDA-approved breakthrough in lumpectomy surgery that helps surgeons achieve optimum results during their procedures. A non-invasive medical device, MarginProbe examines excised tissue during lumpectomy surgery and can detect the presence or absence of cancer cells on the margins. This provides vital, real time information to surgeons when it matters ...
ByDilon Technologies Inc. based in Newport News, VIRGINIA (USA)
Our product pipeline shows the progress we’re making on clinical programs currently in development to create mRNA medicines for a wide range of diseases and conditions. We are proud of the advancements we’ve made in pioneering new mRNA vaccines and treatments that may have the potential to treat and prevent rare ...
ByModerna, Inc. based in Cambridge, MASSACHUSETTS (USA)
IMMUNOSCORE® IC is intended for the detection of PD-L1 protein and the concomitant detection of CD8 + cells in Non-Small Cell Lung cancer (NSCLC) ...
ByVeracyte based in Marseille Cedex 9, FRANCE
You need a complete answer to provide the best ...
ByBiocept based in San Diego, CALIFORNIA (USA)
Using our platform, we are developing mRNA medicines for diverse uses and delivering them to patients across the globe. We are currently focusing on 4 medical areas - infectious diseases, immuno-oncology, rare diseases and autoimmune ...
ByModerna, Inc. based in Cambridge, MASSACHUSETTS (USA)